Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8628112rdf:typepubmed:Citationlld:pubmed
pubmed-article:8628112lifeskim:mentionsumls-concept:C0035820lld:lifeskim
pubmed-article:8628112lifeskim:mentionsumls-concept:C1280551lld:lifeskim
pubmed-article:8628112lifeskim:mentionsumls-concept:C0205101lld:lifeskim
pubmed-article:8628112lifeskim:mentionsumls-concept:C0232338lld:lifeskim
pubmed-article:8628112lifeskim:mentionsumls-concept:C0741968lld:lifeskim
pubmed-article:8628112lifeskim:mentionsumls-concept:C0006462lld:lifeskim
pubmed-article:8628112lifeskim:mentionsumls-concept:C0301630lld:lifeskim
pubmed-article:8628112lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:8628112lifeskim:mentionsumls-concept:C0123905lld:lifeskim
pubmed-article:8628112pubmed:issue1lld:pubmed
pubmed-article:8628112pubmed:dateCreated1996-6-24lld:pubmed
pubmed-article:8628112pubmed:abstractTextThe effects of the 5-HT1A receptor agonist with anxiolytic properties, buspirone and ipsapirone, in the external carotid bed of anaesthetized dogs were analyzed. Since these agonists produce several vascular effects via activation of both 5-HT receptors and alpha1-adrenoceptors, their effects were compared with those elicited by the 5-HT agonist, quipazine, and the alpha1-adrenoceptor agonist, methoxamine. 1-Min intracarotid (i.c.) infusions of buspirone (300 microgram/min), ipsapirone (40 microgram/min), quipazine (300 microgram/min) and methoxamine (15 microgram/min) produced consistent decreases in external carotid blood flow (ECBF); since these changes in blood flow were not accompanied by modifications in systemic blood pressure, the agonists produced parallel increases in external carotid resistance. After interruption of the sympathetic tone by bilateral cervical vagosympathectomy, the vasoconstrictor responses to all the agonists remained unaffected. The intravenous (i.v.) administration of the nonselective 5-HT1-like receptor antagonist, methiothepin (1-100 microgram/kg), potently and dose-dependently antagonized buspirone-, ipsapirone- and quipazine-induced vasoconstriction; methiothepin similarly antagonized the vasoconstrictor responses to methoxamine. Interestingly, the alpha1-adrenoceptor antagonist, prazosin (1-100 microgram/kg, i.v.), also antagonized the vasoconstrictor responses to buspirone, ipsapirone and methoxamine in a dose-dependent manner. Finally, buspirone (300 microgram/min, i.c.) and ipsapirone (40 microgram/min, i.c.) did not modify the responses to noradrenaline (10 microgram/min, i.c.) or tyramine (100 microgram/min, i.c.). It is concluded that canine external carotid vasoconstriction induced by buspirone and ipsapirone is mainly mediated by activation of alpha1-adrenoceptors located in vascular smooth muscle. These data further highlight the ability of the above anxiolytics to produce significant vascular effects under in vivo conditions.lld:pubmed
pubmed-article:8628112pubmed:languageenglld:pubmed
pubmed-article:8628112pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8628112pubmed:citationSubsetIMlld:pubmed
pubmed-article:8628112pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8628112pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8628112pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8628112pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8628112pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8628112pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8628112pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8628112pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8628112pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8628112pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8628112pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8628112pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8628112pubmed:statusMEDLINElld:pubmed
pubmed-article:8628112pubmed:issn0024-3205lld:pubmed
pubmed-article:8628112pubmed:authorpubmed-author:HongEElld:pubmed
pubmed-article:8628112pubmed:authorpubmed-author:VillalónC MCMlld:pubmed
pubmed-article:8628112pubmed:authorpubmed-author:TerrónJ AJAlld:pubmed
pubmed-article:8628112pubmed:authorpubmed-author:Ramírez-San...lld:pubmed
pubmed-article:8628112pubmed:issnTypePrintlld:pubmed
pubmed-article:8628112pubmed:volume58lld:pubmed
pubmed-article:8628112pubmed:ownerNLMlld:pubmed
pubmed-article:8628112pubmed:authorsCompleteYlld:pubmed
pubmed-article:8628112pubmed:pagination63-73lld:pubmed
pubmed-article:8628112pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:8628112pubmed:meshHeadingpubmed-meshheading:8628112-...lld:pubmed
pubmed-article:8628112pubmed:meshHeadingpubmed-meshheading:8628112-...lld:pubmed
pubmed-article:8628112pubmed:meshHeadingpubmed-meshheading:8628112-...lld:pubmed
pubmed-article:8628112pubmed:meshHeadingpubmed-meshheading:8628112-...lld:pubmed
pubmed-article:8628112pubmed:meshHeadingpubmed-meshheading:8628112-...lld:pubmed
pubmed-article:8628112pubmed:meshHeadingpubmed-meshheading:8628112-...lld:pubmed
pubmed-article:8628112pubmed:meshHeadingpubmed-meshheading:8628112-...lld:pubmed
pubmed-article:8628112pubmed:meshHeadingpubmed-meshheading:8628112-...lld:pubmed
pubmed-article:8628112pubmed:meshHeadingpubmed-meshheading:8628112-...lld:pubmed
pubmed-article:8628112pubmed:meshHeadingpubmed-meshheading:8628112-...lld:pubmed
pubmed-article:8628112pubmed:meshHeadingpubmed-meshheading:8628112-...lld:pubmed
pubmed-article:8628112pubmed:meshHeadingpubmed-meshheading:8628112-...lld:pubmed
pubmed-article:8628112pubmed:meshHeadingpubmed-meshheading:8628112-...lld:pubmed
pubmed-article:8628112pubmed:meshHeadingpubmed-meshheading:8628112-...lld:pubmed
pubmed-article:8628112pubmed:meshHeadingpubmed-meshheading:8628112-...lld:pubmed
pubmed-article:8628112pubmed:meshHeadingpubmed-meshheading:8628112-...lld:pubmed
pubmed-article:8628112pubmed:meshHeadingpubmed-meshheading:8628112-...lld:pubmed
pubmed-article:8628112pubmed:meshHeadingpubmed-meshheading:8628112-...lld:pubmed
pubmed-article:8628112pubmed:meshHeadingpubmed-meshheading:8628112-...lld:pubmed
pubmed-article:8628112pubmed:meshHeadingpubmed-meshheading:8628112-...lld:pubmed
pubmed-article:8628112pubmed:meshHeadingpubmed-meshheading:8628112-...lld:pubmed
pubmed-article:8628112pubmed:meshHeadingpubmed-meshheading:8628112-...lld:pubmed
pubmed-article:8628112pubmed:meshHeadingpubmed-meshheading:8628112-...lld:pubmed
pubmed-article:8628112pubmed:year1996lld:pubmed
pubmed-article:8628112pubmed:articleTitleRole of alpha1-adrenoceptors in the reduction of external carotid blood flow induced by buspirone and ipsapirone in the dog.lld:pubmed
pubmed-article:8628112pubmed:affiliationTerapéutica Experimental, CINVESTAV, México.lld:pubmed
pubmed-article:8628112pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8628112pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8628112lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8628112lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8628112lld:pubmed